Healthcare
Maze Therapeutics, Inc.(MAZE)
Live Price
Offline$25.35
+2.05% today
1Y Change
+104.78%
Window
Jun 27, 2025 โ Jun 17, 2026
- Market Cap
- $1.50B
- Revenue Growth
- -100.0%
- EPS Growth
- -4020.3%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 27, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Maze Therapeutics, Inc. (MAZE) is a Healthcare stock with a market cap of $1.50B and listed on NASDAQ. The stock last traded around $25.35 and up 104.8% across the available one-year price window (Jun 27, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of -4020.3%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS -4020.3%, free cash flow -250.7% with operating margin 0.0% and ROIC -37.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MAZE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at -4020.3%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -2.0% | -7.2% | -10.6% |
2026 Mar 25, 2026 | +11.0% | -0.1% | -8.4% | -18.0% |
2025 Nov 6, 2025 | +10.8% | -3.5% | +7.5% | +40.8% |
Benchmark Edge
MAZE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MAZE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MAZE Max Drawdown
-54.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MAZE and SPY.
Company Overview
Maze Therapeutics, Inc.
NASDAQ Global Market
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
- Leadership
- Jason V. Coloma
- IPO Date
- Jan 31, 2025
- Employees
- 125
- Street Address
- 171 Oyster Point Blvd
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 850 5070
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.3
Growth
- Revenue
- -100.0%
- EPS
- -4020.3%
- Free Cash Flow
- -250.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -40.7%
- ROIC
- -37.7%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 15.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.